Morgan Stanley’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.6M | Buy |
1,024,011
+529,444
| +107% | +$2.9M | ﹤0.01% | 3968 |
|
|
2025
Q1 | $3.11M | Buy |
494,567
+303,698
| +159% | +$1.91M | ﹤0.01% | 4301 |
|
|
2024
Q4 | $786K | Sell |
190,869
-7,611
| -4% | -$31.4K | ﹤0.01% | 5212 |
|
|
2024
Q3 | $663K | Buy |
198,480
+109,499
| +123% | +$366K | ﹤0.01% | 5268 |
|
|
2024
Q2 | $265K | Buy |
88,981
+20,754
| +30% | +$61.8K | ﹤0.01% | 5557 |
|
|
2024
Q1 | $235K | Sell |
68,227
-229,779
| -77% | -$793K | ﹤0.01% | 5677 |
|
|
2023
Q4 | $399K | Buy |
298,006
+263,292
| +758% | +$353K | ﹤0.01% | 5704 |
|
|
2023
Q3 | $75.7K | Sell |
34,714
-3,077
| -8% | -$6.71K | ﹤0.01% | 6001 |
|
|
2023
Q2 | $90.3K | Buy |
37,791
+37,407
| +9,741% | +$89.4K | ﹤0.01% | 5997 |
|
|
2023
Q1 | $710 | Sell |
384
-55
| -13% | -$102 | ﹤0.01% | 7390 |
|
|
2022
Q4 | $848 | Sell |
439
-427,966
| -100% | -$827K | ﹤0.01% | 7488 |
|
|
2022
Q3 | $660K | Buy |
+428,405
| New | +$660K | ﹤0.01% | 5120 |
|
|
2022
Q2 | – | Sell |
-589
| Closed | -$1K | – | 7974 |
|
|
2022
Q1 | $1K | Buy |
+589
| New | +$1K | ﹤0.01% | 7873 |
|
|
2021
Q2 | – | Sell |
-1,000
| Closed | -$3K | – | 7804 |
|
|
2021
Q1 | $3K | Buy |
+1,000
| New | +$3K | ﹤0.01% | 7222 |
|
|
2019
Q4 | – | Sell |
-114
| Closed | -$1K | – | 6763 |
|
|
2019
Q3 | $1K | Sell |
114
-5,545
| -98% | -$48.6K | ﹤0.01% | 6578 |
|
|
2019
Q2 | $42K | Buy |
+5,659
| New | +$42K | ﹤0.01% | 5681 |
|